Article info

Original research
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

Authors

  1. Correspondence to Dr Paul Nghiem; pnghiem{at}uw.edu
View Full Text

Citation

Nghiem P, Bhatia S, Lipson EJ, et al
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

Publication history

  • Accepted March 16, 2021
  • First published April 20, 2021.
Online issue publication 
May 06, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.